{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-008096","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.582086+00:00","generated_at":"2026-06-25T21:44:09.694212+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Reneo Q1 net loss $13.0M; STRIDE enrollment 50% done; LC-FAOD data in July 2022","bullets":["Net loss of $13.0M ($0.53/share) vs $7.2M loss ($3.48/share) in Q1 2021.","Cash, equivalents and short-term investments of $138.7M as of March 31, 2022.","R&D expenses rose to $9.3M from $5.5M, driven by STRIDE and FORWARD studies.","Enrolled 100th patient in STRIDE Phase 2b PMM trial; target enrollment 200.","Phase 1b and FORWARD natural history study results in LC-FAOD expected July 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-008096","json":"https://secwatch.observer/filing/0001558370-22-008096.json","markdown":"https://secwatch.observer/filing/0001558370-22-008096.md","text":"https://secwatch.observer/filing/0001558370-22-008096.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000155837022008096/0001558370-22-008096-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000155837022008096/rphm-20220510x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:44:09.694212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}